MSK surgeons present strategies for increasing survival in soft tissue sarcoma patients

May 16, 2016

Up to 50% of patients with soft tissue sarcoma (STS) develop lung metastases. Effective systemic therapies for metastatic STS are currently limited; when possible, surgical removal of the lung metastases (known as pulmonary metastasectomy, PM) is the preferred treatment. However, guidelines for the performance of PM for STS do not exist and decisions to operate are often made on an individual basis. In a presentation at the 96th AATS Annual Meeting, researchers from Memorial Sloan Kettering Cancer Center share the results of their experience with more than 500 patients with pulmonary metastases from STS and describe prognostic factors associated with improved survival.

Baltimore, MD, May 16, 2016 - Approximately 12,000 new cases of soft tissue sarcoma (STS) are diagnosed in the U.S. annually, resulting in nearly 5,000 deaths. Up to half of STS patients develop one or more lung metastases. Without effective systemic therapies, doctors often rely on pulmonary metastasectomy (PM), surgical removal of the pulmonary metastases, although current data for the practice specific to STS are limited. In a presentation at the 96th AATS Annual meeting, Neel P. Chudgar, MD, from the Department of Surgery at Memorial Sloan Kettering Cancer Center (New York) presents survival data and prognostic factors based on a large, single-institution database of STS patients who have undergone pulmonary metastasectomy.

"The present study differs from previous publications in that we used a larger single-institution cohort, which increases the power to potentially identify significant differences, and we focused on STS exclusively to enhance the homogeneity of the study population," explained Dr. Chudgar. The database included 803 patients who underwent PM for sarcoma between September 1991 and June 2014. After excluding patients who had primary bone sarcomas, underwent diagnostic resection, underwent PM at another hospital, or did not undergo resection of their primary tumor, 539 patients who underwent 760 curative-intent PMs were studied.

The investigators found that the median overall survival after the first PM was 33.2 months and the median disease-free survival was 6.8 months. Thirty-four percent of patients were alive after 5 years and 23% were alive after 7 years.

The researchers then analyzed the data to see if they could identify factors associated with prolonged survival. They found that leiomyosarcoma histologic subtype, primary tumor size less than or equal to 10 cm, increasing time from primary tumor resection to development of pulmonary metastases, and less than or equal to three initial lung metastases, were all significantly associated with longer overall survival. Minimally invasive resections were also associated with longer overall survival (median, 44.3 months), compared with open surgery (median, 29.9 months). However, the authors attribute the reduced risk associated with minimally invasive surgery to patient selection, since 81% of these patients had only one or two pulmonary metastases.

"Our results indicate that the preoperative determination of disease characteristics can assist surgeons in selecting patients who may achieve longer survival with PM," commented senior author David R. Jones, MD, Professor and Chief of the Thoracic Surgery Service at Memorial Sloan Kettering Cancer Center. "Until there is an improved understanding of the underlying biologic mechanisms of metastases and further identification of druggable targets, PM remains the best available treatment for metastatic STS."

American Association for Thoracic Surgery

Related Sarcoma Articles from Brightsurf:

Researchers uncover crucial gene for growth of Ewing sarcoma
Researchers have discovered a gene that is critical for the development of Ewing sarcoma, a rare type of developmental cancer that presents in bones and soft tissues.

Immunotherapy combo halts rare, stage 4 sarcoma in teen
The patient, whose tumor responded within two weeks after receiving the combination, resumed normal activity and was in a complete remission at the time of the report.

Oncotarget: Exosomes secreted under hypoxia enhance stemness in Ewing's sarcoma
The cover for issue 40 of Oncotarget features Figure 5, ''miR-210 silences the proapoptosis member CASP8AP2,'' by Kling, et al. which reported that hypoxic Ewing's sarcoma cells release exosomes that promote sphere formation, a stem-like phenotype, in EWS cells by enhancing survival.

Chemotherapy is used to treat less than 25% of people with localized sarcoma
UCLA researchers have found that chemotherapy is not commonly used when treating adults with localized sarcoma, a rare type of cancer of the soft tissues or bone.

Dana-Farber study advances understanding of rare sarcoma
In this study, scientists discover how abnormal protein disrupts gene expression in synovial sarcoma.

Finding hints at novel target for Ewing sarcoma therapy
A genetic code-reading machine that is overactive in the pediatric cancer Ewing sarcoma causes cell structures called nucleoli to break up, researchers found.

Much shorter radiation treatment found to be safe, effective for people with soft tissue sarcoma
A new study led by researchers at UCLA found that treating soft tissue sarcoma with radiation over a significantly shorter period of time is safe, and likely just as effective, as a much longer conventional course of treatment.

B cells: New allies in sarcoma immunotherapy?
How can we improve and better personalize the treatment of soft tissue sarcomas, these particularly resistant and aggressive forms of cancer?

B-cell enrichment predictive of immunotherapy response in melanoma, sarcoma and kidney cancer
Multiple studies out in Nature indicate that a patient's response to immune checkpoint blockade may depend on B cells located in special structures within the tumor.

Combination of chemo and diabetes drugs shows potential for treating Ewing sarcoma
Houston Methodist researchers propose a combination of two well-known drugs as a new treatment option for Ewing sarcoma -- one of them typically used to treat diabetes.

Read More: Sarcoma News and Sarcoma Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to